NXTC.US NextCure  Inc

Healthcare Biotechnology USA Stocks
6.68 USD
Close of Nov 17, 2026
1.55 15.74
Market cap
USD 30.6M
P/E
-
P/B
5.33x
ROE
-764.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is NXTC.US undervalued?

Graham number

The Graham number of NextCure  Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NextCure  Inc fundamental analysis

No fundamental analysis for NextCure  Inc yet.

NextCure  Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NextCure  Inc

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of …

Full company profile